Samples in the TCGA-PAAD cohort were segregated into two groups according to the median value for CAST, CCDC6, and ERLIN1. Moreover, CAST, CCDC6 and ERLIN1 low expression are suggestive of a lower IC50, indicating their potential as novel indicators for the drug susceptibility of Erlotinib, Sunitinib and Imatinib (Figure 7C). The gene discussed is CCDC6; the disease is pancreatic adenocarcinoma.